摘要
目的利用网络药理学技术探讨清咳平喘颗粒治疗新型冠状病毒肺炎(COVID-19)的作用机制。方法使用TCMSP、Swiss Target Prediction等数据库预测清咳平喘颗粒的主要成分和其作用靶点,再与CTD、GeneCards数据库得到的COVID-19的疾病靶点交集整合,获得清咳平喘颗粒治疗COVID-19的潜在靶点。借助String平台绘制蛋白质相互作用(PPI)网络及筛选核心靶点,并开展基因本体(GO)注释功能与京都基因与基因组百科全书(KEGG)通路富集分析。依托Cytoscape软件绘制“成分-靶点-通路”的网络图。采用Autodock分子对接技术将关键靶点与清咳平喘颗粒中关键成分进行验证。结果共获得261个药物-疾病共同靶点,包括TNF、IL6、ALB、AKT1、VEGFA在内的91个核心靶点。GO富集分析、KEGG富集分析分别共得到条目1508个、152个,涵盖Toll-like receptor(TLR)信号通路、IL-17信号通路和HIF-1信号通路等。分子对接结果显示,麻黄碱、苦杏仁苷是清咳平喘颗粒抗COVID-19主要活性成分。结论运用网络药理学得到了清咳平喘颗粒抗COVID-19的作用靶点和通路,为进一步探讨清咳平喘颗粒治疗COVID-19的作用机制提供依据。
Objective To explore the mechanism of Qingke Pingchuan Granule in treatment of COVID-19.Methods TCMSP,Swiss Target Prediction and other databases were used to predict the main components and targets of Qingke Pingchuan Granules.Then,it was comprehensive with the disease targets of COVID-19 obtained from CTD and GeneCards databases to obtain the potential targets of Qingke Pingchuan Granules in treatment of COVID-19.PPI network was mapped with String platform and core targets were screened,and enrichment analysis of GO function and KEGG pathway was carried out.Cytoscape software was used to map the component-Target-pathway network.The key targets with the key components Qingke Pingchuan granules was verified by adopting the Autodock molecular docking technology.Results A total of 261 drug-disease common targets were obtained,including 91 core targets including TNF,IL6,ALB,AKT1,and VEGFA.A total of 1508 and 152 items were obtained by GO and KEGG enrichment analysis,respectively,covering Toll-like signaling pathway,IL-17 signaling pathway and HIF-1 signaling pathway.Molecular docking results showed that ephedrine and amygdalin were the main active components of Qingke Pingchuan Granules against COVID-19.Conclusion The target and pathway of COVID-19,which provides a realistic basis for further exploring the mechanism of the treatment of COVID-19.
作者
孙宝迪
夏斌
俞燕露
史芸轩
邵旦兵
SUN Baodi;XIA Bin;YU Yanlu;SHI Yunxuan;SHAO Danbing(Sir Run Run Hospital,Nanjing Medical University,Nanjing 210001,China;School of Health,Shandong University of Traditional Chinese Medicine,Jinan 250355,China)
出处
《药物评价研究》
CAS
2023年第10期2116-2125,共10页
Drug Evaluation Research
基金
南京医科大学科技发展基金项目(NMUB20220054)。